This Plain Language Summary of Publication article (PLSP) from Immunotherapy, the COMPACT study evaluated SDZ ETN (ErelziTM), an etanercept biosimilar, in 1466 patients across Europe and Canada with rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis. These rheumatic conditions primarily affect joints and spine but can also impact other organs like the skin and heart. Over a 12-month period, patients experienced consistent improvements in disease symptoms with SDZ ETN treatment, with no new side effects reported.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study’ and was published in Advances in Therapy.

Visit Springer Nature Link using the link to read the original article.